HIV / AIDS in the News

Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug - BioPharma Dive

 

How Health Budget Cuts Are Harming People With HIV Around the World - Pulitzer Center

 

$600 million in Trump administration health cuts will hit California HIV programs - Los Angeles Times - Los Angeles Times

 

Trump administration cutting millions in Illinois HIV prevention grants, citing 'agency priorities' - Chicago Sun-Times

 

Trump administration plans to rescind $600M in public health funds from 4 Democrat states, including Illinois - ABC7 Chicago

 

New York Department of Health offers free HIV self-testing kits - WBNG

 

‘A lot of people are scared’: HIV patients face uncertainty over Florida ADAP cuts - The Miami Times

 

[Press release] UNSW: 'Systemic failure': Global reviews show extent of injecting drug use and infectious diseases in prisons - European AIDS Treatment Group

 

Oral HIV self-test approved for sale in Canada - CBC

 

[Press release] Queen Mary University of London: First of its kind daily HIV treatment shows promising results - European AIDS Treatment Group

 

Gov’t targets 40 per cent reduction in new HIV infections by 2030 - Jamaica Gleaner

 

Gilead tops 4Q expectations, but Yeztugo forecast disappoints - FirstWord Pharma

 

Medscape: Cancer screening gaps leave people with HIV at elevated risk - European AIDS Treatment Group

 

Oral HIV self-test approved for sale in Canada - Yahoo News Canada

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

 

Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates - TradingView

 

aidsmap: Immigration and poverty tied to heightened HIV risk in the Netherlands - European AIDS Treatment Group

 

GILD: 2025 revenue and EPS rose on HIV and liver drugs; 2026 outlook strong despite Veklury decline - TradingView

 

New York Department of Health offers free HIV self-testing kits - wcax.com

 

Oral HIV self-test approved for sale, advocates say it’s key to elimination - Toronto Star

 

New oral HIV at-home test coming to Canada - Yahoo News Canada

 

Data-Driven, People-Centered Digital Tools for HIV Treatment and Prevention - Johns Hopkins Bloomberg School of Public Health